Aarti Pharmalabs Limited (NSE:AARTIPHARM)

Market Cap	83.05B
Revenue (ttm)	21.15B
Net Income (ttm)	2.72B
Shares Out	90.63M
EPS (ttm)	30.04
PE Ratio	30.50
Forward PE	n/a
Dividend	3.50 (0.39%)
Ex-Dividend Date	Feb 14, 2025

Volume	162,468
Average Volume	307,174
Open	920.00
Previous Close	916.35
Day's Range	910.00 - 932.40
52-Week Range	551.05 - 949.50
Beta	-0.48
RSI	59.42
Earnings Date	Aug 5, 2025

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medication...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 2,095
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AARTIPHARM

Financial Performance

In 2024, Aarti Pharmalabs's revenue was 21.15 billion, an increase of 14.17% compared to the previous year's 18.53 billion. Earnings were 2.72 billion, an increase of 25.59%.